This is a phase 2 study to look at the safety and how well tolerated a combined thiamine with biotin therapy will be in HD patients  in mild to moderate stages. They will evaluate the biological effect of the treatment in the central nervous system  using as the main biomarker, the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. The treatment will be oral(by mouth) over  a year.

Our main hypothesis is that the oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients